THE INTERACTION OF HUMAN PANCREATIC GROWTH HORMONE RELEASING FACTOR 1–44 WITH SOMATOSTATIN IN VIVO IN NORMAL MAN
Ryan R. Davies, S. J. Turner, Hans Ørskov, Desmond G. Johnston
Abstract
Ryan R. Davies, S. J. Turner, Hans Ørskov, Desmond G. Johnston
Abstract
The interaction between the stimulatory effects of hpGRF 1-44 and the inhibitory effects of somatostatin on GH release have been investigated in six normal male subjects receiving continuous 4 h infusions of these peptides alone and in combination. hpGRF 1-44 0.3 microgram/kg/h alone produced a peak GH response of 27.0 +/- 7.6 mU/l (mean +/- SEM). Somatostatin 1.0 microgram/kg/h markedly inhibited the GH response to hpGRF 1-44 with mean levels less than 4.0 mU/l during the infusion, though a rebound rise in GH levels to 26.1 +/- 9.0 mU/l was observed at the end of the infusion period. Somatostatin 0.2 microgram/kg/h inhibited the GH response to hpGRF 1-44 to a lesser degree (peak GH during the infusion 11.7 +/- 2.5 mU/l) and the rebound rise in GH levels (maximum 13.2 +/- 4.3 mU/l) was less than that observed with high dose somatostatin. During somatostatin 1.0 microgram/kg/h alone GH levels were suppressed less than 1.0 mU/l followed by a rebound at the end of the infusion in only two subjects. These data demonstrate a dose-dependent inhibition of hpGRF 1-44 by somatostatin in vivo in man.
OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The interaction between the stimulatory effects of hpGRF 1-44 and the inhibitory effects of somatostatin on GH release have been investigated in six normal male subjects receiving continuous 4 h infusions of these peptides alone and in combination. hpGRF 1-44 0.3 microgram/kg/h alone produced a peak GH response of 27.0 +/- 7.6 mU/l (mean +/- SEM). Somatostatin 1.0 microgram/kg/h markedly inhibited the GH response to hpGRF 1-44 with mean levels less than 4.0 mU/l during the infusion, though a rebound rise in GH levels to 26.1 +/- 9.0 mU/l was observed at the end of the infusion period. Somatostatin 0.2 microgram/kg/h inhibited the GH response to hpGRF 1-44 to a lesser degree (peak GH during the infusion 11.7 +/- 2.5 mU/l) and the rebound rise in GH levels (maximum 13.2 +/- 4.3 mU/l) was less than that observed with high dose somatostatin. During somatostatin 1.0 microgram/kg/h alone GH levels were suppressed less than 1.0 mU/l followed by a rebound at the end of the infusion in only two subjects. These data demonstrate a dose-dependent inhibition of hpGRF 1-44 by somatostatin in vivo in man.
Key concepts: Somatostatin, Endocrinology, Internal medicine, In vivo, Growth hormone, Somatropin, Peptide hormone, Hormone